Antiangiogenic strategies and agents in clinical trials

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 20-27

  Rosen, Lee ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Cytotoxic chemotherapy; Vascular endothelial growth factor

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COMBRETASTATIN; ENDOSTATIN; MONOCLONAL ANTIBODY LM 609; SQUALAMINE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR VASCULARIZATION;

EID: 0033995511     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-20     Document Type: Conference Paper

References (76)

1. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181-196.
2. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
3. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491-502.
4. Gimbrone MA Jr. Leapman SB, Cotran RS et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-276.
5. Gimbrone MA Jr, Cotran RS, Leapman SB et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974;52:413-427.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
7. Dameron KM, Volpert OV, Tainsky MA et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
8. Cockerill GW, Gamble JR. Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995;159:113-160.
9. Giatromanolaki A, Sivridis E, Koukourakis MI et al. Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 1999;11:205-212.
10. Dazzi C, Cariello A, Maioli P et al. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 1999;24:81-88.
11. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993;55:371-374.
12. Toi M, Inada K, Suzuki H et al. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
13. Strohmeyer D, Rossing C, Strauss F et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000;42:26-33.
14. Patel T, Roychowdhury DF, Chadalavada R. Angiogenesis in esophageal cancer. J Clin Oncol 1999;18:614a.
15. Fruehauf JP, Naab T, Mehta R et al. Prognostic value of angiogenesis index in colorectal cancer. J Clin Oncol 1999;18:284a.
16. Ahn CS, Kang JY, Rho JS et al. Angiogenesis in squamous epithelial lesions of the uterine cervix. J Clin Oncol 1997;16:552a.
17. Rajkumar SV, Leong T, Fonseca R et al. Bone marrow angiogenesis has prognostic value in multiple myeloma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1999;18:19a.
18. Bellamy WT, Richter L, Frutiger Y et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
19. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
20. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
21. McAuslan BR, Bender V, Reilly W et al. New functions of epidermal growth factor: stimulation of capillary endothelial cell migration and matrix dependent proliferation. Cell Biol Int Rep 1985;9:175-182.
22. Ferrara N, Houck K, Jakeman L et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
23. Rosen EM, Grant DS, Kleinman HK et al. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 1993;47:227-234.
24. Rosen EM, Laterra J, Joseph A et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996;67:248-255.
25. Relf M, LeJeune S, Scott PAE et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
26. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
27. Smith DR, Polverini PJ, Kunkel SL et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179:1409-1415.
28. Gawrychowski K, Skopinska-Rózewska E, Barcz E et al. Angiogenic activity and interleukin-8 content of human ovarian cancer ascites. Eur J Gynaecol Oncol 1998;19:262-264.
29. Frater-Schroder M, Risau W, Hallmann R et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987;84:5277-5281.
30. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
31. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
32. Dinney CP, Bielenberg DR, Perrotte P et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808-814.
33. Shaipe RJ, Byers HR, Scott CF et al. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990;82:848-853.
34. Maione TE, Gray GS, Petro J et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-79.
35. Tolsma SS, Volpert OV, Good DJ et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
36. Clapp C, Martial JA, Guzman RC et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993;133:1292-1299.
37. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111-119.
38. Johnson MD, Kim HR, Chesler L et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
39. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998;8:171-177.
40. Gomez DE, Alonso DF, Yoshiji H et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122.
41. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994;86:299-304.
42. Kruger A, Sanchez-Sweatman OH, Martin DC et al. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998;16:2419-2423.
43. Cornelius LA, Nehring LC, Harding E et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-6852.
44. Kleiner DE, Stetler-Stevenson WG. Matrix melalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(suppl):S42-S51.
45. Giannelli G, Brassard J, Foti C et al. Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B. Lab Invest 1996;74:1091-1104.
46. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993;67:1-17.
47. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997;49:123-131.
48. Huang PH, McBride WG, Tuman WG. Interaction of thalidomide with DNA of rabbit embryos: a possible explanation for its immunosuppressant and teratogenic effects. Pharmacol Toxicol 1999;85:103-104.
49. Haslett PA, Klausner JD, Makonkawkeyoon S et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-1179.
50. Dixon SC, Kruger EA, Bauer KS et al. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999;43(suppl):S78-S84.
51. Wernert N, Stanjek A, Kiriakidis S et al. Inhibition of angiogenesis in vivo by ets-1 antisense oligonucleotides-inhibition of Ets-1 transcription factor expression by the antibiotic fumagillin. Angew Chem Int Ed Engl 1999;38:3228-3231.
52. Turk BE, Su Z, Liu JO. Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 1998;6:1163-1169.
53. Yoshida T, Kaneko Y, Tsukamoto A et al. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res 1998;58:3751-3756.
54. O'Leary JJ, Shapiro RL, Ren CJ et al. Anti-angiogenic effects of 9-amino-20(S)-camptothecin (9-AC), topolecan (TTN), and CPT-11 studied in the mouse cornea model. J Clin Oncol 1998;17:248a.
55. Klauber N, Parangi S, Flynn E et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-86.
56. Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849.
57. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
58. Eppenberger U, Kueng W, Schlaeppi J-M et al. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-3136.
59. Rosen L, Mulay M, Mayers A et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. J Clin Oncol 1999;18:161a.
60. Shaheen RM, Davis DW, Liu W et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-5416.
61. Evans LM, Itri LM, Campion M et al. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 1991;10:39-50.
62. Fischl MA, Finkelstein DM, He W et al. A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379-384.
63. Morris AK, Valley AW. Overview of the management of AIDS-related Kaposi's sarcoma. Ann Pharmacother 1996;30:1150-1163.
64. Tryfonas GI, Tsikopoulos G, Liasidou E et al. Conservative treatment of hemangiomas in infancy and childhood with interferon-alpha 2a. Pediatr Surg Int 1998;13:590-593.
65. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-4077.
66. Mellstedt H, Osterborg A, Bjorkholm M et al. Treatment of multiple myeloma with interferon alpha: the Scandinavian experience. Br JHaematol 1991;79(suppl 1):21-25.
67. Mughal TI, Thomas MR, Robinson WA. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology 1991;48:365-368.
68. Price CG, Rohatiner AZ, Steward W et al. Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann Oncol 1991;2(suppl 2):141-145.
69. Dreno B, Claudy A, Meynadier J et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991;125:456-459.
70. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145-154.
71. Steward WP. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 1999;43(suppl):S56-S60.
72. Wilding G, Small E, Collier M et al. A phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. J Clin Oncol 1999;18:323a.
73. D'Olimpio J, Hande K, Collier M et al. Phase I study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. J Clin Oncol 1999;18:160a.
74. Goel R, Hirte H, Major P et al. Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients. J Clin Oncol 1999;18:160a.
75. Tolcher A, Rowinsky EK, Rizzo J et al. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin. J Clin Oncol 1999;18:160a.
76. Eatock M, Cassidy J, Johnson J et al. A phase I study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS270231) with 5FU and folinic acid. J Clin Oncol 1999;18:209a.